

New York Pharma Forum 24th Annual General Assembly

- *The Promise of Stem Cell & Regenerative Medicine* -

Friday, December 6, 2013
3:00 p.m. to 5:30 p.m.

New York Pharma Forum's Annual General Assembly will feature a stellar, high-profile panel of experts to explore the current state of stem cell and regenerative medicine applications for the pharma industry. Attendees will have the rare opportunity to hear from a Japanese policymaker about the government's efforts to advance development of these applications in Japan. The program will also explore the role of academic and nonprofit research organizations, examine investment trends and describe how one large biotech company is leveraging new stem cell-based screens for use in drug discovery.

Speakers

Ron Winslow (moderator)
Deputy Bureau Chief, Health and Science, The Wall Street Journal

Eric Chiao, MD, PhD
Associate Director, Center for Cell Biology Research, Head, Stem Cell Biology, Biogen Idec

Michael Keyoung, MD, PhD
Managing Director, Burrill & Company

Teruo Okano, PhD
Vice President, Tokyo Women's Medical University
Professor and Director, Institute of Advanced Biomedical Engineering and Science (TWMU)
President, Japanese Society of Regenerative Medicine

Yasuyuki Sahara, MD
Senior Coordinator for Health, Minister's Secretariat, Ministry of Health, Labour and Welfare, Japan

Susan Solomon
CEO and Co-Founder, The New York Stem Cell Foundation

Program Highlights

- Mr. Winslow will give an overview of the topic, and present his own perspective as one of the foremost American journalists who has covered life science issues and trends.
- Dr. Chiao will describe how Biogen Idec is leveraging new stem cell-based screens for use in drug discovery.
- Dr. Keyoung will examine the funding situation and investment opportunities in stem cells and regenerative medicine in the US and Asia.
- Dr. Okano will address the current state of stem cells and regenerative medicine research in Japan.
- Dr. Sahara will discuss the Japanese government's policy/initiatives to advance development of stem cell and regenerative medicine applications.
- Ms. Solomon will address the NYSCF's role and model to advance stem cells and regenerative medicine research.

Location: New York Athletic Club (President's Room, 10th fl.), 180 Central Park South, New York City

Cost: Members – Free; Nonmembers – Suggested \$30 donation

Dress: The New York Athletic Club requires jackets for men and comparable attire for women

Registration: To register, please visit: <http://www.nypharmaforum.org/GA>

For more information, please contact Jacob Seal at 212-583-1043, ext. 16, or jseal@bridgeny.com

General Assembly Speaker Bios

Dr. Eric Chiao

Associate Director, Center for Cell Biology Research, Head, Stem Cell Biology, Biogen Idec

In February 2013, Dr. Chiao joined Biogen Idec where he is establishing a stem cell lab focused on developing new stem cell based screens for use in drug discovery. He previously served as the head of the Pluripotent Stem Cell lab in the Early Investigative Safety group at Hoffmann-La Roche; his lab developed novel stem cell based assays for examining drug induced cardiac arrhythmias, viral infection of human hepatocytes, and a high throughput screen for drug induced teratogenic effects. Before Roche, he served as the founding Director of the Human Pluripotent Stem Cell facility at Stanford, where he had completed his post-doctoral studies on developing human embryonic stem cells as a model system for studying endoderm formation. Dr. Chiao received his PhD in genetics from Columbia University.

Dr. Michael Keyoung

Managing Director, Burrill & Company

Dr. Keyoung has more than 15 years of healthcare and life sciences experience through his role as physician, consultant and investor. He serves as the Managing Director in Venture Capital and Private Equity at Burrill & Company. He is also General Partner of Burrill's global life sciences private equity fund and portfolio manager of Burrill's U.S., European and Asian public portfolio companies, and he leads Pan-Asia transaction business as Head of Asia. Dr. Keyoung has served on the boards of private biopharma companies and organizations in the U.S. and in Asia. He is currently on UCSF Medical School's Adjunct faculty and involved with Clinical and Translational Science Institute and at T1 Translational Catalyst Program.

Dr. Teruo Okano

Director, Institute of Advanced Biomedical Engineering and ScienceTokyo Women's Medical University

Dr. Okano is currently Director of the Institute of Advanced Biomedical Engineering and Science and professor at Tokyo Women's Medical University. His research interests involve the use of intelligent biomaterials for biomedical research applications such as microdomain structured polymers, stimuli-responsive polymers, hydrogels, polymeric micelles, modulated drug release, targetable drug carriers, blood compatible polymers, cell engineering, tissue engineering, and artificial organs as well as others. His research group has succeeded in harvesting cultured cells as viable and confluent cell layers by modifying temperature-responsive polymer, poly(N-isopropylacrylamide) (PIPAAm) onto ordinary polystyrene tissue culture dish surfaces. Based on this temperature-responsive surface, they have proposed a new concept of "cell sheet engineering" which introduces an alternate path for tissue and organ regeneration, using only manipulated cell sheets. Dr. Okano has held academic positions at institutions in Japan and the U.S. and is the author or co-author of more than 500 peer-reviewed journal articles as well as over 250 books and book chapters.

Dr. Yasuyuki Sahara

Senior Coordinator for Health, Minister's Secretariat, Labour and Welfare, Japan

Dr. Sahara received his MD degree from the School of Medicine at Kanazawa University in 1989 and a Master of Public Health degree from Harvard University in 1995. After working as a pediatrician at the Kanagawa Children's Medical Center in Yokohama, he joined the Ministry of Health and Welfare in 1991. Since then, he has held various positions in the Ministry, World Health Organization in Geneva and the Wakayama Prefecture Government. In 2006, he became the director of the Office of Patient Safety, Health Policy Bureau. In 2011 he became the Director of the Division for Research and Development, Health Policy Bureau, and was responsible for the planning of the new law for regenerative medicine. He began his current position in 2013.

Ms. Susan Solomon

CEO and Co-Founder, The New York Stem Cell Foundation

Ms. Solomon is CEO and Co-Founder of The New York Stem Cell Foundation (NYSCF), a non-profit organization established in 2005 to accelerate cures through stem cell research. A longtime health-care advocate, Ms. Solomon is a founding member and current President of New Yorkers for the Advancement of Medical Research, is on the Executive Committee for the Alliance for Regenerative Medicine, and she has been a member of the Board of Directors of the Juvenile Diabetes Research Foundation, New York Chapter. She was also a member of the Strategic Planning Committee of the Empire State Stem Cell Board.